Emistat-FT
Generic Name
Ondansetron
Manufacturer
Square Pharmaceuticals PLC.
Country
Bangladesh
Loading images...
Price Details
Current market pricing information
| Variant | Unit Price | Strip Price |
|---|---|---|
| emistat ft 4 mg flash tablet | ৳ 6.00 | ৳ 60.00 |
Description
Overview of the medicine
Emistat-FT 4 mg Flash Tablet contains Ondansetron, an anti-emetic used to prevent nausea and vomiting caused by chemotherapy, radiation therapy, and surgery. The flash tablet formulation dissolves rapidly in the mouth without water.
Uses & Indications
Dosage
Adults
Highly emetogenic chemotherapy: 8 mg orally 30 minutes before chemotherapy, then 8 mg 8 hours after the first dose, and then 8 mg every 12 hours for 1-2 days. Post-operative nausea/vomiting: 8 mg orally 1 hour before anesthesia or 8 mg post-operatively.
Elderly
No specific dosage adjustment is generally required, but monitor for QT prolongation due to potential age-related changes in cardiac function.
Renal_impairment
No dosage adjustment is required in patients with renal impairment.
How to Take
Place the flash tablet on the tongue; it will rapidly disintegrate and can be swallowed with or without water. Do not chew or crush the tablet.
Mechanism of Action
Ondansetron is a selective 5-HT3 receptor antagonist. It works by blocking serotonin from binding to 5-HT3 receptors located both peripherally on vagal nerve terminals and centrally in the chemoreceptor trigger zone (CTZ) in the brain, thereby preventing nausea and vomiting.
Pharmacokinetics
Onset
Within 30 minutes of oral administration.
Excretion
Primarily via urine (approximately 5-10% as unchanged drug), with the remainder as metabolites. A small portion is excreted in feces.
Half life
Approximately 3 to 6 hours in adults, but can be longer in elderly patients and those with hepatic impairment.
Absorption
Rapidly and completely absorbed from the gastrointestinal tract. Peak plasma concentrations are achieved in approximately 1.5 to 2 hours. Oral bioavailability is approximately 60% due to first-pass metabolism.
Metabolism
Extensively metabolized in the liver primarily by cytochrome P450 enzymes (CYP1A2, CYP2D6, CYP3A4) via hydroxylation followed by glucuronide or sulfate conjugation.
Side Effects
Contraindications
- Hypersensitivity to ondansetron or any component of the formulation.
- Concomitant use with apomorphine due to risk of profound hypotension and loss of consciousness.
Drug Interactions
Tramadol
Ondansetron may reduce the analgesic effect of tramadol and may increase the risk of seizures.
Apomorphine
Concomitant use is contraindicated due to reports of profound hypotension and loss of consciousness.
QT-prolonging drugs
Use with caution with other drugs known to prolong the QT interval (e.g., antiarrhythmics, antipsychotics, certain antibiotics) as it may increase the risk of cardiac arrhythmias.
Phenytoin, Carbamazepine, Rifampicin
These enzyme inducers may reduce plasma concentrations of ondansetron.
Storage
Store below 30°C in a dry place, protected from light and moisture. Keep out of reach of children.
Overdose
Symptoms of overdose include transient visual disturbances, constipation, severe hypotension, syncope, tachycardia, and potential QT interval prolongation. Management involves symptomatic and supportive treatment, including ECG monitoring for QT prolongation.
Pregnancy & Lactation
Pregnancy Category B. Studies in animals have not shown harm, but human data is limited. Use only if clearly needed and the potential benefits outweigh the risks. Ondansetron is excreted into breast milk; breastfeeding is not recommended during treatment.
Frequently Asked Questions
Common questions about this medicine
Pack Sizes
Shelf Life
24 months from the date of manufacture.
Availability
Pharmacies, Hospitals
Approval Status
Approved
Patent Status
Generic available
WHO Essential Medicine
YesClinical Trials
Ondansetron has undergone extensive clinical trials demonstrating its efficacy and safety in preventing chemotherapy-induced nausea and vomiting (CINV), radiation-induced nausea and vomiting (RINV), and post-operative nausea and vomiting (PONV). Its oral disintegrating tablet formulation ensures rapid onset of action.
Lab Monitoring
- ECG monitoring is recommended in patients with risk factors for QT prolongation (e.g., congenital long QT syndrome, electrolyte abnormalities, or concomitant use of other QT-prolonging drugs).
Doctor Notes
- Ensure patients are aware of the proper administration technique for flash tablets (dissolve on tongue, do not chew).
- Advise patients to report any signs of hypersensitivity, severe constipation, or cardiac symptoms promptly.
- Caution in patients with underlying cardiac conditions, especially those at risk for QT prolongation.
- Review concomitant medications for potential drug interactions, particularly with apomorphine and other QT-prolonging agents.
Patient Guidelines
- Take this medicine exactly as prescribed by your doctor.
- Do not take more or less than the recommended dose.
- Inform your doctor if you experience any unusual or severe side effects.
- The tablet dissolves on the tongue; no water is needed for administration.
Missed Dose Advice
If you miss a dose, take it as soon as you remember. If it is almost time for your next dose, skip the missed dose and continue with your regular dosing schedule. Do not take a double dose to make up for a missed one.
Driving Precautions
Ondansetron may cause dizziness or fatigue. Patients should be advised to avoid driving or operating machinery if they experience these effects.
Lifestyle Advice
- Maintain adequate hydration, especially during episodes of nausea and vomiting. Avoid alcohol during treatment as it may exacerbate side effects.
Alternative Medicines in Bangladesh
Similar medicines available in the market
Global Brand Names
International brand names for this medicine
Related
Medicines
Explore similar medicines to find the best option for your healthcare needs.
Azi S
Square Pharmaceuticals Ltd.
Azilpres
Specific manufacturer varies by region (e.g., Square Pharmaceuticals Ltd. in BD for a generic Azilsartan product)
Axxo
Square Pharmaceuticals Ltd.
Avloquin-H
General Pharmaceuticals Ltd.
Axovit
Reputable Pharma Ltd.
Exalin
Square Pharmaceuticals Ltd.
Azelec
Square Pharmaceuticals Ltd.
EuroORS
Euro Pharma Ltd.
Timozin
MediCorp Pharma Ltd.
Lotenate Plus
General Pharmaceuticals Ltd.